| Clinical data | |
|---|---|
| Other names | 4-Me-αMT; 4-Me-AMT; 4-Methyl-αMT; 4-Methyl-AMT; 4,α-Dimethyltryptamine; 4,α-DMT; MP-809; MP809; Methyl-2-methyltryptamine |
| Routes of administration | Oral |
| Drug class | Antidepressant |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H16N2 |
| Molar mass | 188.274 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
4-Me-αMT (developmental code name MP-809), or 4-Me-AMT, also known as 4-methyl-α-methyltryptamine or as 4,α-dimethyltryptamine (4,α-DMT), is an experimental antidepressant of the tryptamine and α-alkyltryptamine families that was never marketed. It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine (αMT) and α-ethyltryptamine (αET).
4-Me-αMT is active at a dose of 20 to 60 mg orally in humans, though described as being an antidepressant rather than a hallucinogen. It was found to be effective as an antidepressant in preliminary clinical studies. Alexander Shulgin has said that 4-Me-αMT produced some feelings of unreality at 20 mg, as well as skin flushing, muscle tightness, and mydriasis. However, he has said that it could not be called a hallucinogen at assessed doses and has listed the hallucinogenic dose as being greater than 60 mg.
4-Me-αMT partially reverses reserpine-induced behavioral depression in rodents (by up to 60%), but does not produce hyperlocomotion. This was the case at a dose of 50 mg/kg, whereas αMT produced clear hyperlocomotion and near-fully reversed reserpine-induced hypoactivity (by 95%) at a dose of 15 mg/kg. Hence, 4-Me-αMT shows reduced antidepressant- and psychostimulant-like potency compared to αMT. It is also less active than αET. The drug is said to have very weak monoamine oxidase inhibition.
Analogues of 4-methyl-AMT include α-methyltryptamine (AMT), 4-methyl-AET, 4-methyl-DMT, 4-HO-AMT, 4-HO-AET, and RS134-49 (4-methyl-THPI), among others.
4-Me-αMT was first described in the scientific literature by 1962. It was investigated as an antidepressant by Sandoz in Canada in the early 1960s, although it was never marketed.
| Tryptamines |
|
|---|---|
| 4-Hydroxytryptamines and esters/ethers |
|
| 5-Hydroxy- and 5-methoxytryptamines |
|
| N-Acetyltryptamines |
|
| α-Alkyltryptamines |
|
| α-Ketotryptamines | |
| Cyclized tryptamines |
|
| Isotryptamines | |
| Related compounds |
|